Results 61 to 70 of about 21,696 (215)

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

Frontiers in Oncology
BackgroundRuxolitinib has been approved by the US FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and primary myelofibrosis.
Sivahari P. Gorantla, Sivahari P. Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Chandrasekaran Dinesh, Vijay Boddu, Justus Duyster, Nikolas von Bubnoff   +7 more
doaj   +1 more source

Fatal ruxolitinib-related JC virus meningitis

, 2017
We report a possible association between ruxolitinib and JC virus meningitis. A 72-year-old man with myelofibrosis started treatment with ruxolitinib. Fourteen days later, the patient presented to the emergency department with fever and nausea.
Vicente Martín, Juan J. Ballesta, Ballesta, Begoña, Ballesta, Juan J., Martín, Vicente, Begoña Ballesta, Héctor González, González, Héctor   +7 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease

, 2021
BACKGROUND Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies
Locatelli F.
core   +2 more sources

Triggering of Suicidal Erythrocyte Death by Ruxolitinib

, 2015
Background/Aims: The JAK1/JAK2 tyrosine kinase inhibitor ruxolitinib is widely used for the treatment of myeloproliferative neoplasm-associated myelofibrosis and other malignancies. Most important side effects include anemia.
Marilena Briglia, Antonella Fazio, Kousi Alzoubi, Florian Lang, Caterina Faggio, Stefan Laufer   +5 more
core   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Aberrant antigen expression on mast cells (MCs) is one of the most accurate diagnostic markers for clonal MC diseases (CMCD). Although the coexistence of normal and pathologic MCs is frequently seen, the disease characteristics associated with it have been minimally investigated.
Abdulrazzaq Alheraky, Kees Meijer, Marije Nijk, Saskia K. Klein, Hanneke N. G. Oude Elberink, Ido P. Kema, André B. Mulder   +6 more
wiley   +1 more source

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Infection and Drug Resistance, 2020
Emiko Sakiyama, Yoshiaki Chinen, Taku Tsukamoto, Tomoko Takimoto-Shimomura, Saeko Kuwahara-Ota, Yayoi Matsumura-Kimoto, Yuji Shimura, Tsutomu Kobayashi, Shigeo Horiike, Junya Kuroda Division of Hematology and Oncology, Department of Medicine, Kyoto ...
Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y, Shimura Y, Kobayashi T, Horiike S, Kuroda J   +9 more
doaj  

Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series

Head &Neck, EarlyView.
ABSTRACT Introduction A Phase II trial demonstrated that neoadjuvant cemiplimab was associated with pathologic complete response (pCR) in 51% of patients with locoregionally advanced cutaneous squamous cell carcinoma (cuSCC). We evaluated real‐world radiographic and pathologic responses to neoadjuvant cemiplimab and assessed radiologic–pathologic ...
Whitney Jin, Ryan K. Rigsby, Kim Ely, Austin Hoke, Robert Sinard, Kyle Mannion, Jill Gilbert, Lindsay Mundy, Alexander Langerman, Sarah Rohde, Barbara Murphy, Eben Rosenthal, Mitra Mehrad, Michael C. Topf, Jennifer H. Choe   +14 more
wiley   +1 more source

Stathmin 1 Inhibition Amplifies Ruxolitinib-induced Apoptosis In Jak2v617f Cells. [PDF]

, 2016
The JAK/STAT pathway is constitutively activated in myeloproliferative neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor. The JAK2(V617F) mutation leads to constitutive STAT3 phosphorylation and potentially leads to inhibition ...
Machado-Neto, João Agostinho, Lorand-Metze, Irene, da Silva Santos Duarte, Adriana, Traina, Fabiola, Favaro, Patricia, Costa, Fernando Ferreira, de Melo Campos, Paula, Lazarini, Mariana, Saad, Sara Teresinha Olalla   +8 more
core   +1 more source